Companies can count A/R as revenue, I believe, when they have reason to expect payment. SKTO took a pre-emptive $12,706,300 charge against possible bad debt in the Q3 2013 fins. That was very prudent, even if their blockbusters like Dharmanol and T-Hydrocan and their other licensed products eventually cover that debt. For bank accounts, is it cut and dry now? I've read conflicting reports about whether banks will still risk entering the mmj arena. I think SKTO is in good shape if FINRA comes calling. Benz scrutinizes the books; he personally reported the Q3 numbers in the conference call. No attorney of his stature and reputation would do that if something were amiss. The four companies in the FINRA alert that street.com later identified (SKTO was not included) may have something to worry about. Have you sold?